Pharmafile Logo
Pharmafocus logo
Advanced Search

lynparza

Showing 15 posts of 35 posts found.

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

June 9, 2023
Research and Development AstraZeneca, Cancer, MSD, NICE, Oncology, lynparza, pharma

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) posted a positive recommendation …

News
european_commission_web

European green light for Lynparza in germline BRCA-mutated metastatic pancreatic cancer

July 8, 2020
Research and Development, Sales and Marketing AstraZeneca, Cancer, Europe, MSD, lynparza

The European Commission has awarded approval to AstraZeneca and MSD’s Lynparza (olaparib) for germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer, with …

News
lynparza

Lynparza secures CHMP recommendation in first-line BRCA-mutated metastatic pancreatic cancer

June 1, 2020
Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza

Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has just secured recommendation for approval from the European Medicines …

News
fda2outsideweb

Lynparza combo authorised in US for first-line maintenance of HRD-positive advanced ovarian cancer

May 11, 2020
Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer

Lynparza (olaparib), developed by AstraZeneca and MSD, has secured FDA approval when paired with bevacizumab as a first-line maintenance treatment …

News
astrazeneca_plaque

Japan grants orphan drug designation to Lynparza for BRCA+ unresectable pancreatic cancer

March 19, 2020
Research and Development, Sales and Marketing AstraZeneca, Japan, lynparza, pharma

AstraZeneca has confirmed that its PARP inhibitor Lynparza (olaparib) has been awarded orphan drug designation in Japan for the maintenance …

News
shutterstock_38078521

AstraZeneca’s cediranib combo misses main goal in platinum-sensitive relapsed ovarian cancer

March 13, 2020
Medical Communications, Research and Development AstraZeneca, cediranib, lynparza, pharma, trial failure

Newly revealed Phase 3 data has shown that AstraZeneca’s oral vascular endothelial growth factor receptor (VEGFR) inhibitor cediranib, when combined …

News
fda2outsideweb

Lynparza secures accelerated FDA review for metastatic castration-resistant prostate cancer

January 20, 2020
Sales and Marketing Cancer, FDA, lynparza, pharma

Following the recommendation of the tablet formulation of the drug for use on the NHS in England and Wales, news …

News
lynparza

Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer

January 16, 2020
Sales and Marketing AstraZeneca, MSD, NHS, NICE, UK, lynparza

It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured …

News
5204602349_c87b204860_b

FDA advisory committee approves the use of Lynparza in pancreatic cancer

December 18, 2019
Research and Development AstraZeneca, Cancer, Merck, Pancreatic cancer, lynparza

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of AstraZeneca and Merck’s Lynparza (olaparib) to treat pancreatic …

News

NICE authorises Lynparza for NHS use in all BRCA-mutated ovarian cancer cases

December 2, 2019
Sales and Marketing Cancer, NHS, NICE, lynparza, ovarian cancer, pharma

NICE has given its recommendation for the routine use on the NHS in England and Wales of AstraZeneca and MSD’s …

News
lynparza

Lynparza extends progression-free survival in first-line advanced ovarian cancer, with or without BRCA mutations

August 14, 2019
Research and Development AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma

New Phase 3 data has emerged on AstraZeneca and MSD’s Lynparza (olaparib), showing that the PARP inhibitor achieved its primary …

News
astrazeneca_plaque

AstraZeneca’s Lynparza meets primary endpoint in Phase 3 prostate cancer trial

August 7, 2019
Research and Development Lynpraza, PARP inhibitor, lynparza, pharma, prostate cancer

AstraZeneca’s PARP inhibitor Lynparza was successful in improving progression free survival in a Phase 3 trial of patients with metastatic …

News

AstraZeneca’s Lynparza approved via Cancer Drugs Fund for BRCA+ gynaecological cancers

July 26, 2019
Medical Communications, Sales and Marketing AstraZeneca, Cancer, Cancer Drugs Fund, NHS, NICE, UK, lynparza, pharma

NICE has published final guidance which approves AstraZeneca’s Lynparza (olaparib) for use on the NHS as a maintenance therapy for …

News
lynparza

EU approval for MSD and AZ’s Lynparza in first-line BRCA-mutated advanced ovarian cancer

June 18, 2019
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma

AstraZeneca and MSD’s jointly-developed therapy Lynparza (olaparib) has scored its third EU approval, the pair announced, with authorisation for the …

News
credit_-_daniel_leal-olivas-afp

AZ and MSD’s Lynparza secures CHMP nod in first-line BRCA-mutated ovarian cancer

April 29, 2019
Sales and Marketing AstraZeneca, CHMP, Cancer, MSD, lynparza, ovarian cancer, pharma

AstraZeneca and MSD’s Lynparza (olaparib) has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use …

News

Latest content

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024